XORTX Therapeutics Inc. SEC filings XRTX
XORTX Therapeutics Inc. has 291 filings in SEC EDGAR's recent list, going back to Jan 25, 2018. Its latest annual report, Form 20-F, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 27, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2023 | — |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1729214
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.